Published in J Clin Invest on March 01, 2007
Immune Regulation in Ulcerative Colitis or Crohn s Disease | NCT00001184
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine. Cell Host Microbe (2008) 11.08
Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell (2007) 8.42
IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest (2008) 6.17
Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer (2009) 5.31
STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med (2009) 4.94
Loss of integrin alpha(v)beta8 on dendritic cells causes autoimmunity and colitis in mice. Nature (2007) 4.94
Microbes in gastrointestinal health and disease. Gastroenterology (2008) 4.65
The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol (2012) 3.88
Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev (2007) 3.61
Caspase-8 regulates TNF-α-induced epithelial necroptosis and terminal ileitis. Nature (2011) 3.61
Regulation of tissue homeostasis by NF-kappaB signalling: implications for inflammatory diseases. Nat Rev Immunol (2009) 3.51
Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis. Inflamm Bowel Dis (2009) 3.32
FADD prevents RIP3-mediated epithelial cell necrosis and chronic intestinal inflammation. Nature (2011) 3.17
The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology (2014) 2.73
T cell transfer model of chronic colitis: concepts, considerations, and tricks of the trade. Am J Physiol Gastrointest Liver Physiol (2008) 2.71
TH9 cells that express the transcription factor PU.1 drive T cell-mediated colitis via IL-9 receptor signaling in intestinal epithelial cells. Nat Immunol (2014) 2.62
In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat Med (2014) 2.54
Crohn's disease-associated adherent-invasive E. coli are selectively favoured by impaired autophagy to replicate intracellularly. Cell Microbiol (2009) 2.23
Colon-specific delivery of a probiotic-derived soluble protein ameliorates intestinal inflammation in mice through an EGFR-dependent mechanism. J Clin Invest (2011) 2.16
Crohn disease--associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. J Clin Invest (2011) 2.10
Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. J Clin Invest (2011) 2.09
Role of beta7 integrins in intestinal lymphocyte homing and retention. Curr Mol Med (2009) 1.94
Confocal laser endomicroscopy is a new imaging modality for recognition of intramucosal bacteria in inflammatory bowel disease in vivo. Gut (2010) 1.92
Microbiota innate stimulation is a prerequisite for T cell spontaneous proliferation and induction of experimental colitis. J Exp Med (2010) 1.86
Peptidoglycan recognition proteins protect mice from experimental colitis by promoting normal gut flora and preventing induction of interferon-gamma. Cell Host Microbe (2010) 1.85
The innate immune receptor Nod1 protects the intestine from inflammation-induced tumorigenesis. Cancer Res (2008) 1.78
CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell (2013) 1.71
Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J Exp Med (2009) 1.71
A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis. Am J Pathol (2009) 1.70
Orexigenic hormone ghrelin ameliorates gut barrier dysfunction in sepsis in rats. Crit Care Med (2009) 1.67
Sustained TL1A expression modulates effector and regulatory T-cell responses and drives intestinal goblet cell hyperplasia. Mucosal Immunol (2010) 1.61
Inflammation and colorectal cancer: colitis-associated neoplasia. Semin Immunopathol (2012) 1.61
Histone deacetylase 3 coordinates commensal-bacteria-dependent intestinal homeostasis. Nature (2013) 1.59
Hypoxia-inducible factor augments experimental colitis through an MIF-dependent inflammatory signaling cascade. Gastroenterology (2008) 1.57
TLR2-independent induction and regulation of chronic intestinal inflammation. Eur J Immunol (2010) 1.55
A general O-glycosylation system important to the physiology of a major human intestinal symbiont. Cell (2009) 1.53
Dendritic cell (DC)-specific targeting reveals Stat3 as a negative regulator of DC function. J Immunol (2010) 1.53
Inflammatory bowel disease, past, present and future: lessons from animal models. J Gastroenterol (2008) 1.48
Intestinal E-cadherin Deficiency Aggravates Dextran Sodium Sulfate-Induced Colitis. Dig Dis Sci (2015) 1.43
Evolving paradigms in the pathogenesis of IBD. J Gastroenterol (2009) 1.37
Immunopathology of inflammatory bowel disease. World J Gastroenterol (2014) 1.36
Nutritional basis for colonization resistance by human commensal Escherichia coli strains HS and Nissle 1917 against E. coli O157:H7 in the mouse intestine. PLoS One (2013) 1.34
New pathophysiological insights and modern treatment of IBD. J Gastroenterol (2010) 1.31
Distinct effects of p38alpha deletion in myeloid lineage and gut epithelia in mouse models of inflammatory bowel disease. Gastroenterology (2010) 1.31
NOD2, an intracellular innate immune sensor involved in host defense and Crohn's disease. Mucosal Immunol (2011) 1.30
Latent cytomegalovirus infection exacerbates experimental colitis. Am J Pathol (2009) 1.30
Inflammasomes in intestinal inflammation and cancer. Gastroenterology (2011) 1.28
Immunopathogenesis of inflammatory bowel disease. World J Gastroenterol (2008) 1.28
Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.28
Downregulation of sodium transporters and NHERF proteins in IBD patients and mouse colitis models: potential contributors to IBD-associated diarrhea. Inflamm Bowel Dis (2009) 1.26
Crohn disease: a current perspective on genetics, autophagy and immunity. Autophagy (2011) 1.26
Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest (2011) 1.25
Immunopathogenesis of inflammatory bowel disease. Self Nonself (2011) 1.24
The role of T-regulatory cells and Toll-like receptors in the pathogenesis of human inflammatory bowel disease. Immunology (2008) 1.23
The TLR2-MyD88-NOD2-RIPK2 signalling axis regulates a balanced pro-inflammatory and IL-10-mediated anti-inflammatory cytokine response to Gram-positive cell walls. Cell Microbiol (2008) 1.23
Quantitative metabolomic profiling of serum, plasma, and urine by (1)H NMR spectroscopy discriminates between patients with inflammatory bowel disease and healthy individuals. J Proteome Res (2012) 1.21
Genome sequence of adherent-invasive Escherichia coli and comparative genomic analysis with other E. coli pathotypes. BMC Genomics (2010) 1.21
Intestinal microbiota: shaping local and systemic immune responses. Semin Immunol (2011) 1.21
The paradoxical effects of vitamin D on type 1 mediated immunity. Mol Aspects Med (2008) 1.20
Intestinal CX3C chemokine receptor 1(high) (CX3CR1(high)) myeloid cells prevent T-cell-dependent colitis. Proc Natl Acad Sci U S A (2012) 1.19
Loss of guanylyl cyclase C (GCC) signaling leads to dysfunctional intestinal barrier. PLoS One (2011) 1.17
Gut microbial diversity is reduced by the probiotic VSL#3 and correlates with decreased TNBS-induced colitis. Inflamm Bowel Dis (2011) 1.16
The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol (2009) 1.16
Microbiota downregulates dendritic cell expression of miR-10a, which targets IL-12/IL-23p40. J Immunol (2011) 1.14
T helper type 1 memory cells disseminate postoperative ileus over the entire intestinal tract. Nat Med (2010) 1.13
Intestinal epithelial serum amyloid A modulates bacterial growth in vitro and pro-inflammatory responses in mouse experimental colitis. BMC Gastroenterol (2010) 1.13
Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. Am J Physiol Gastrointest Liver Physiol (2011) 1.12
Paradoxical effects of constitutive human IL-32{gamma} in transgenic mice during experimental colitis. Proc Natl Acad Sci U S A (2010) 1.11
Toll like receptor-5: protecting the gut from enteric microbes. Semin Immunopathol (2007) 1.10
The transcription factor NFATc2 controls IL-6-dependent T cell activation in experimental colitis. J Exp Med (2008) 1.10
Interleukin-23 and Th17 cells in the control of gut inflammation. Mediators Inflamm (2009) 1.10
Associations between genetic polymorphisms in IL-33, IL1R1 and risk for inflammatory bowel disease. PLoS One (2013) 1.10
Polymorphisms in NF-κB, PXR, LXR, PPARγ and risk of inflammatory bowel disease. World J Gastroenterol (2011) 1.08
Animal models of IBD: linkage to human disease. Curr Opin Pharmacol (2010) 1.08
Luminal cathepsin g and protease-activated receptor 4: a duet involved in alterations of the colonic epithelial barrier in ulcerative colitis. Am J Pathol (2009) 1.08
Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology (2012) 1.07
Tomato lycopene extract prevents lipopolysaccharide-induced NF-kappaB signaling but worsens dextran sulfate sodium-induced colitis in NF-kappaBEGFP mice. PLoS One (2009) 1.07
Mechanisms of intestinal inflammation and development of associated cancers: lessons learned from mouse models. Mutat Res (2010) 1.06
The role of polymorphonuclear leukocyte trafficking in the perpetuation of inflammation during inflammatory bowel disease. Inflamm Bowel Dis (2013) 1.05
Abnormally expressed ER stress response chaperone Gp96 in CD favours adherent-invasive Escherichia coli invasion. Gut (2010) 1.05
Mitochondrial antiviral signaling protein (MAVS) monitors commensal bacteria and induces an immune response that prevents experimental colitis. Proc Natl Acad Sci U S A (2011) 1.04
Predictors of clinical and endoscopic findings in differentiating Crohn's disease from intestinal tuberculosis. Dig Dis Sci (2010) 1.04
Tumor fibroblast-derived epiregulin promotes growth of colitis-associated neoplasms through ERK. J Clin Invest (2013) 1.03
Th17-related cytokines: new players in the control of chronic intestinal inflammation. BMC Med (2011) 1.03
Impact of the gut microbiome on mucosal inflammation. Trends Immunol (2013) 1.03
Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology? Inflamm Bowel Dis (2009) 1.03
CD4+CD25+ regulatory T cells suppress Th17-responses in an experimental colitis model. Dig Dis Sci (2010) 1.02
Oral TNF-α gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J Control Release (2010) 1.01
A role of the aryl hydrocarbon receptor in attenuation of colitis. Dig Dis Sci (2011) 1.00
Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis (2015) 1.00
A distal enhancer in Il12b is the target of transcriptional repression by the STAT3 pathway and requires the basic leucine zipper (B-ZIP) protein NFIL3. J Biol Chem (2011) 0.98
Role of the enteric microbiota in intestinal homeostasis and inflammation. Free Radic Biol Med (2013) 0.98
Use of butyrate or glutamine in enema solution reduces inflammation and fibrosis in experimental diversion colitis. World J Gastroenterol (2012) 0.98
Interleukin-21 triggers effector cell responses in the gut. World J Gastroenterol (2010) 0.98
Fc gamma receptor signaling in mast cells links microbial stimulation to mucosal immune inflammation in the intestine. Am J Pathol (2008) 0.98
TNF-alpha-induced up-regulation of pro-inflammatory cytokines is reduced by phosphatidylcholine in intestinal epithelial cells. BMC Gastroenterol (2009) 0.98
Toll-like receptor activation in basophils contributes to the development of IgG4-related disease. J Gastroenterol (2012) 0.98
Galectin-4 controls intestinal inflammation by selective regulation of peripheral and mucosal T cell apoptosis and cell cycle. PLoS One (2008) 0.97
Isolation of Mycobacterium avium subspecies paratuberculosis reactive CD4 T cells from intestinal biopsies of Crohn's disease patients. PLoS One (2009) 0.97
Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature (2001) 33.12
A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature (2001) 28.24
Inflammatory bowel disease. N Engl J Med (2002) 21.17
Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med (2005) 14.50
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest (2006) 11.89
Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science (2005) 11.31
Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol (2001) 11.07
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A (2003) 10.71
The immunology of mucosal models of inflammation. Annu Rev Immunol (2001) 9.08
CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science (2005) 8.97
Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science (2004) 8.68
Mucosal flora in inflammatory bowel disease. Gastroenterology (2002) 8.42
Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med (2004) 7.93
Regulation of intestinal alpha-defensin activation by the metalloproteinase matrilysin in innate host defense. Science (1999) 6.49
RICK/Rip2/CARDIAK mediates signalling for receptors of the innate and adaptive immune systems. Nature (2002) 5.95
Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet (2004) 5.83
NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol (2004) 5.59
Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest (2004) 5.39
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology (2005) 5.26
Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest (2004) 5.14
A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am J Hum Genet (2006) 5.10
NODs: intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol (2003) 5.07
Reduced Paneth cell alpha-defensins in ileal Crohn's disease. Proc Natl Acad Sci U S A (2005) 5.05
Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology (1998) 5.02
Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology (2004) 4.89
Tolerance exists towards resident intestinal flora but is broken in active inflammatory bowel disease (IBD) Clin Exp Immunol (1995) 4.81
Signalling pathways and molecular interactions of NOD1 and NOD2. Nat Rev Immunol (2006) 4.55
Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity (2006) 3.98
CARD15/NOD2 functions as an antibacterial factor in human intestinal epithelial cells. Gastroenterology (2003) 3.70
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med (2005) 3.56
The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol (2004) 3.54
Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N Engl J Med (2003) 3.49
Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease. Gastroenterology (2005) 3.41
Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm Bowel Dis (2006) 3.29
Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science (1995) 3.16
CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med (1998) 3.01
Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells. J Immunol (2005) 3.00
Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology (2005) 2.85
Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat Biotechnol (2003) 2.80
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology (2004) 2.75
A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol (1998) 2.74
A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum (2005) 2.65
A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.45
Sargramostim for active Crohn's disease. N Engl J Med (2005) 2.24
Nucleotide binding oligomerization domain 2 deficiency leads to dysregulated TLR2 signaling and induction of antigen-specific colitis. Immunity (2006) 2.06
Inducible and constitutive beta-defensins are differentially expressed in Crohn's disease and ulcerative colitis. Inflamm Bowel Dis (2003) 2.06
Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest (2003) 2.02
Review article: the role of bacteria in onset and perpetuation of inflammatory bowel disease. Aliment Pharmacol Ther (2006) 1.97
Cdcs1, a major colitogenic locus in mice, regulates innate and adaptive immune response to enteric bacterial antigens. Gastroenterology (2005) 1.81
The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J Med Microbiol (2006) 1.79
Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. J Immunol (1997) 1.69
T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis. J Exp Med (2002) 1.69
Ribosomal DNA sequence analysis of mucosa-associated bacteria in Crohn's disease. Inflamm Bowel Dis (2004) 1.65
Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infect Immun (2004) 1.53
Selective adherence of IgA to murine Peyer's patch M cells: evidence for a novel IgA receptor. J Immunol (2002) 1.39
ABCB1/MDR1 gene determines susceptibility and phenotype in ulcerative colitis: discrimination of critical variants using a gene-wide haplotype tagging approach. Hum Mol Genet (2006) 1.26
Review article: practical management of inflammatory bowel disease patients taking immunomodulators. Aliment Pharmacol Ther (2005) 1.20
A risk haplotype in the Solute Carrier Family 22A4/22A5 gene cluster influences phenotypic expression of Crohn's disease. Gastroenterology (2005) 1.19
Intestinal disease in Hermansky-Pudlak syndrome: occurrence of colitis and relation to genotype. Clin Gastroenterol Hepatol (2006) 1.19
Excess IL-12 but not IL-23 accompanies the inflammatory bowel disease associated with common variable immunodeficiency. Gastroenterology (2006) 1.18
Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med (2005) 1.17
Complications of biological therapy for inflammatory bowel diseases. Curr Opin Gastroenterol (2006) 1.12
Helminths and mucosal immune modulation. Ann N Y Acad Sci (2006) 1.09
The nature of colitis in chronic granulomatous disease. J Pediatr Gastroenterol Nutr (2003) 1.04
Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Disord (2006) 1.03
Understanding immune-microbial homeostasis in intestine. Immunol Res (2002) 1.00
Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment Pharmacol Ther (2003) 0.99
Maintenance therapy for inflammatory bowel disease. Am J Gastroenterol (2003) 0.98
A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis. Aliment Pharmacol Ther (2006) 0.97
Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study. Aliment Pharmacol Ther (2001) 0.96
Current limitations of IBD treatment: where do we go from here? Ann N Y Acad Sci (2006) 0.94
CD4 T cells monospecific to ovalbumin produced by Escherichia coli can induce colitis upon transfer to BALB/c and SCID mice. Int Immunol (2001) 0.94
Surgery for inflammatory bowel diseases. Dig Dis (2003) 0.90
Pilot feasibility studies of leukocytapheresis with the Adacolumn Apheresis System in patients with active ulcerative colitis or Crohn disease. J Clin Gastroenterol (2006) 0.89
Leukocytapheresis therapy for steroid-naïve patients with active ulcerative colitis: its clinical efficacy and adverse effects compared with those of conventional steroid therapy. J Gastroenterol Hepatol (2005) 0.87
Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol (2007) 6.32
Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest (2004) 5.14
Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. Genome Biol (2012) 4.68
Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology (2005) 4.68
TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J Immunol (2004) 3.79
A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity (2009) 2.59
Positive and negative transcriptional regulation of the Foxp3 gene is mediated by access and binding of the Smad3 protein to enhancer I. Immunity (2010) 1.68
T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance. Nature (2008) 1.68
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res (2008) 1.26
Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest (2011) 1.25
Lymphocyte-dependent and Th2 cytokine-associated colitis in mice deficient in Wiskott-Aldrich syndrome protein. Gastroenterology (2007) 1.21
Intestinal disease in Hermansky-Pudlak syndrome: occurrence of colitis and relation to genotype. Clin Gastroenterol Hepatol (2006) 1.19
Proinflammatory cytokines underlying the inflammation of Crohn's disease. Curr Opin Gastroenterol (2010) 1.18
P-selectin and P-selectin glycoprotein ligand 1 are major determinants for Th1 cell recruitment to nonlymphoid effector sites in the intestinal lamina propria. J Exp Med (2003) 1.15
Antibodies to complement receptor 3 treat established inflammation in murine models of colitis and a novel model of psoriasiform dermatitis. J Immunol (2006) 1.03
Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease. Immunol Rev (2014) 0.95
Lack of compartmentalization of HIV-1 quasispecies between the gut and peripheral blood compartments. J Infect Dis (2011) 0.90
Complement-dependent injury and protection in a murine model of acute dextran sulfate sodium-induced colitis. J Immunol (2012) 0.86
Inflammatory bowel diseases: emerging therapies and promising molecular targets. Front Biosci (Schol Ed) (2012) 0.83
Insights into the mechanism of oral tolerance derived from the study of models of mucosal inflammation. Ann N Y Acad Sci (2004) 0.82
Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm Bowel Dis (2009) 0.79
GAIN for loss: adalimumab for infliximab-refractory Crohn disease. Ann Intern Med (2007) 0.78
Gut permeability and colitis. Gastroenterology (2009) 0.76
Natural killer T cells in mucosal homeostasis. Ann N Y Acad Sci (2004) 0.76
CD1d-restricted T cell pathways at the epithelial-lymphocyte-luminal interface. J Pediatr Gastroenterol Nutr (2004) 0.75